For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Fever pitch: The road ahead for rheumatic fever
+News
Fever pitch: The road ahead for rheumatic fever
Sunday 7 July 2019, 09:00 AM

Five years of effort and money have been put into cutting the high rates of rheumatic fever in New Zealand, but the sector has fallen well short of reaching the targets set. Fiona Thomas takes a look at how we arrived at this point and what's ahead
SHAME is the common denominator in conversations about rheumatic fever in New Zealand.
The disease, which hospitalises about 137 people a year, is so
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.